Abarelix

Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.

Product Specifications

CAS Number

[183552-38-7]

Product Name Alternative

R3827; PPI 149

UNSPSC

12352209

Hazard Statement

H302, H312, H332

Target

GnRH Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Abarelix.html

Purity

99.72

Solubility

H2O : 42 mg/mL (ultrasonic; warming) |DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCCNC(C)C)NC([C@H](CC(C)C)NC([C@@H](CC(N)=O)NC([C@H](CC2=CC=C(C=C2)O)N(C([C@H](CO)NC([C@@H](CC3=CC=CN=C3)NC([C@@H](CC4=CC=C(Cl)C=C4)NC([C@@H](CC5=CC=C6C=CC=CC6=C5)NC(C)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)CCC1)=O

Molecular Formula

C72H95ClN14O14

Molecular Weight

1416.06

Precautions

H302, H312, H332

References & Citations

[1]Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70 (4) :580-7.|[2]Kirby RS, et al. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104 (11) :1580-4.|[3]Debruyne F, et al. Abarelix for injectable suspension: first-in-class releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2 (6) :677-96.